I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 0.9397 USD -2.01% Market Closed
Market Cap: 76m USD
Have any thoughts about
I-Mab?
Write Note

I-Mab
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

I-Mab
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I-Mab
NASDAQ:IMAB
Revenue
ÂĄ27.6m
CAGR 3-Years
-74%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
ÂĄ17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
ÂĄ5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Revenue
ÂĄ8.3B
CAGR 3-Years
37%
CAGR 5-Years
31%
CAGR 10-Years
27%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
ÂĄ46.7B
CAGR 3-Years
30%
CAGR 5-Years
42%
CAGR 10-Years
51%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
ÂĄ2.9B
CAGR 3-Years
59%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

I-Mab
Glance View

Market Cap
76m USD
Industry
Biotechnology

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

IMAB Intrinsic Value
0.7454 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is I-Mab's Revenue?
Revenue
27.6m CNY

Based on the financial report for Dec 31, 2023, I-Mab's Revenue amounts to 27.6m CNY.

What is I-Mab's Revenue growth rate?
Revenue CAGR 5Y
-12%

The average annual Revenue growth rates for I-Mab have been -74% over the past three years , -12% over the past five years .

Back to Top